Health-related quality of life in lower-risk MDS patients compared with age- and sex-matched reference populations: a European LeukemiaNet study

Reinhard Stauder1 · Ge Yu2 · Karin A. Koinig1 · Tim Bagguley2 · Pierre Fenaux3 · Argiris Symeonidis4 · Guillermo Sanz5,6 · Jaroslav Cermak7 · Moshe Mittelman8 · Eva Hellström-Lindberg9 · Saskia Langemeijer10 · Mette Skov Holm11 · Krzysztof Małdry12 · Luca Malcovati13 · Aurelia Tatic14 · Ulrich Germing15 · Aleksandar Savic16 · Corine van Marrewijk10 · Agnès Guerci-Bresler17 · Elisa Luño18 · Jackie Droste10 · Fabio Efficace19 · Alex Smith2 · David Bowen20 · Theo de Witte21

Received: 21 December 2017 / Revised: 25 January 2018 / Accepted: 30 January 2018 / Published online: 6 March 2018
© The Author(s) 2018. This article is published with open access

Abstract
In myelodysplastic syndromes (MDS), health-related quality of life (HRQoL) represents a relevant patient-reported outcome, which is essential in individualized therapy planning. Prospective data on HRQoL in lower-risk MDS remain rare. We assessed HRQOL by EQ-5D questionnaire at initial diagnosis in 1690 consecutive IPSS-Low/Int-1 MDS patients from the European LeukemiaNet Registry. Impairments were compared with age- and sex-matched EuroQol Group norms. A significant proportion of MDS patients reported moderate/severe problems in the dimensions pain/discomfort (49.5%), mobility (41.0%), anxiety/depression (37.9%), and usual activities (36.1%). Limitations in mobility, self-care, usual activities, pain/discomfort, and EQ-VAS were significantly more frequent in the old, in females, and in those with high comorbidity burden, low haemoglobin levels, or red blood cells transfusion need ($p < 0.001$). In comparison to age- and sex-matched peers, the proportion of problems in usual activities and anxiety/depression was significantly higher in MDS patients ($p < 0.001$). MDS-related restrictions in the dimension mobility were most prominent in males, and in older people ($p < 0.001$); in anxiety/depression in females and in younger people ($p < 0.001$); and in EQ-VAS in women and in persons older than 75 years ($p < 0.05$). Patients newly diagnosed with IPSS lower-risk MDS experience a pronounced reduction in HRQoL and a clustering of restrictions in distinct dimensions of HRQoL as compared with reference populations.

Introduction
Myelodysplastic syndromes (MDS) represent challenging hematopoietic disorders characterized by cytopenias, functional blood defects, and clonal hematopoiesis. The clinical course is characterized by an impaired health-related quality of life (HRQoL), the risk of transformation to acute myeloid leukaemia (AML) and reduced survival in the majority of patients [1]. Based on biological parameters, the patients are classified into different risk groups to predict overall survival (OS) and the risk of AML transformation. The international prognostic scoring system (IPSS) [2] and more recently, the revised IPSS (IPSS-R) [3] represent the gold standard in prognostication of MDS. Based on these scoring systems, IPSS low/intermediate-1 risk and IPSS-R (very) low/intermediate risk are classified as lower-risk MDS with a low propensity to transform to AML [2, 3]. The treatment goals in this cohort of patients are an improvement in cytopenias, prolongation of survival, and improvement and maintenance of HRQoL and functional capacities. IPSS intermediate-2/high and IPSS-R high/very high risk are classified as higher-risk MDS, which are characterized by an increased risk of AML transformation and a short median survival of less than 2 years [1].

Patients with MDS often suffer from a high symptom burden, resulting in restrictions in HRQoL. Assessment of HRQoL provides information on the patient’s perspective and perception, thus representing a relevant patient-reported
outcome (PRO) [1, 4, 5]. The study of HRQoL has become an increasingly critical area of research [6], as limitations in HRQoL are frequently observed in MDS and are only partially explained by anaemia [7, 8]. Moreover, restrictions in HRQoL may predict an unfavourable clinical outcome [9–12]. In addition HRQoL, represents a parameter of response evaluation [1, 13, 14]. Thus, the integration of assessment of HRQoL in MDS has been propagated by clinicians, stakeholders, and authorities [1, 13–15]. However, definitive data on HRQoL in low-risk MDS at initial diagnosis are limited by small sample size [16, 17], selection bias [7, 16, 17], and assessment later after initial diagnosis [7, 11, 16, 18, 19]. In addition, most studies have included patients with higher-risk MDS [9–12, 16, 18–20], AML [10, 11], or CMML [11, 16], which precludes precise interpretation. Lower-risk patients with MDS are typically of advanced age with a median of 74 years at diagnosis [21]. The dissection between age-associated restrictions in HRQoL and the incremental impact of MDS in these patients is relevant, yet has not been analyzed at all.

The main objective of this international prospective cohort observational study is to investigate the HRQoL profile of patients with lower-risk MDS at the time of diagnosis, as compared with the general population matched on age and sex. The incremental impact of MDS on symptom burden is dissected by comparing features in MDS with the general population. A secondary objective is to examine clinical factors associated with HRQoL of these patients.

Materials/methods

Participants

The EUMDS Registry is a prospective, non-interventional longitudinal study, enrolling newly diagnosed patients with IPSS low or intermediate-1 MDS from 145 haematology centres in 17 European countries and Israel. Patients with an IPSS risk intermediate-2 or high, or with therapy-related MDS were excluded. Patients without cytogenetic information were only included if the diagnosis of MDS was morphologically proven, with <5% bone marrow blasts and at most a single cytopenia according to the IPSS. Based on these criteria, exclusively IPPS low or intermediate-1 patients were included in EUMDS.

Therapy is given according to local guidelines [21]. Enrolment was within 100 days of the diagnostic bone marrow aspirate. The average time from date of diagnosis to inclusion was 44 days (standard deviation 28 days). Details on design and data collection have been published elsewhere [21].

As the European Quality of Life five Dimensions (EQ-5D) was not licensed in two countries, 15 countries were included in this analysis. EUMDS (ClinicalTrials.gov: NCT00600860) has been approved by the ethics committee of all participating centres and is performed in accordance with the Declaration of Helsinki. Written informed consent was obtained from all patients.

HRQoL measurement

Patient-reported HRQoL was measured by EQ-5D, at the time of study enrolment. EQ-5D is a validated, generic, HRQoL questionnaire [22], consisting of the EQ-5D descriptive system with five dimensions related to daily activities (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), with three-level answers (no problem, some problems, severe problems), and a visual analogue scale (EQ-VAS). The five dimensions were converted into a single summary index (EQ-5D index) by applying the European value set (EVS) [23]. EQ-VAS [22] is a global evaluation of ‘own health today’ using a health state scale ranging from 0 (worst imaginable) to 100 (best imaginable).

Measures of population norms

The main objective of this paper was to compare the QoL of patients with MDS with general population with a similar age and gender distribution. Therefore, population norms were used as reference values to assess the relative HRQoL of patients in comparison to that of an average person [24]. Population norms are based on descriptions of current health status from population surveys. Nine European countries in this study (Denmark, France, Germany, Greece, Italy, Netherlands, Spain, Sweden, and the UK) have reported a series of tables of age/sex population norms for the EQ-5D for both, profile data and VAS scores [25]. For the five European countries and Israel for which there are no published EQ-5D population norms, we replaced the missing data on the probabilities of being in a given level for each EQ-5D dimension with the mean of the available European countries by matching the combination of age group and gender.

Demographic and clinical parameters

Information on patients’ demographics (age and gender), IPSS-R, co-morbidity index (MDS-CI), haemoglobin (Hb) level at the time of diagnosis, and red blood cell transfusions (RBCT) in the year prior to the diagnosis were recorded [3, 21, 26]. Due to the small number of young adult patients, age was categorized into three groups (<60, 60–75, and 75+ years) to compare HRQoL of different age groups.
Statistical analysis

Differences in response between the five EQ-5D dimensions in patients with MDS and European norms were evaluated using χ² tests. For both EQ-5D index and EQ-VAS, the mean score with standard deviation was calculated. Wilcoxon’s signed ranks tests were conducted to identify any major difference between the MDS patient baseline values and European norms. The relationship between HRQoL and demographic/clinical factors was examined using multilevel linear regression (additional information is available in Supplementary Materials); univariate analysis was performed for age at diagnosis, gender, IPSS-R, MDS-CI, Hb, and RBCT status, and a multivariate analysis was performed adjusting for all other variables. We assessed the discriminative ability of HRQoL not only by a significant difference, but also by a minimally important difference (MID) [27]. The MID is viewed as the smallest difference in score in the domain of interest that is perceived by patients as beneficial or that would result in a change in treatment. See Supplementary Materials for more detail.

All analyses were undertaken in Stata 14 (StataCorp, College Station, TX).

Results

Characteristics of patients

Based on IPSS-scoring, i.e., the gold-standard in classification at the time of start of the registry, 1985 patients were included between December 2007 and January 2016, among which 961 (48.4%) were IPSS low-risk and 912 (45.9%) were IPSS Int-1. IPSS score could not be calculated in 5.6% of patients where cytogenetic testing was not available or had failed. Based on inclusion criteria, exclusively IPSS low or int-1 patients were included. Retrospective classification by IPSS-R revealed a (very) low risk in 24.8% and 37.6%, an intermediate risk in 21.2%, high/very high risk in 6.1%, and classification was unknown in 10.3% of patients. In total, 1690 patients (85.1%) completed both EQ-5D descriptive system and EQ-VAS. Thirty-three patients (1.7%) completed EQ-5D description only, and seven patients (0.3%) completed EQ-VAS only (Table 1). The majority of patients had advanced age (median age: 74 years), and a male preponderance was observed. Nearly half of patients were characterized by Hb levels <10 g/dL at baseline, and more than 30% of patients had received RBCT within 1 year prior to diagnosis. Demographic characteristics of the patients who completed EQ-5D did not differ substantially from the total cohort, showing a similar age distribution and a slightly higher proportion of men. Overall, the HRQoL data in our sample were likely missing at random (Table 1).

Patients with MDS reveal profound impairments in HRQoL

The MDS cohort was characterized by a mean EQ-5D index-score of 0.74 and a mean EQ-VAS of 69.6. A significant proportion of MDS patients reported moderate or severe problems in the dimensions pain/discomfort (49.5%), mobility (41.0%), anxiety/depression (37.9%), and usual activities (36.1%), respectively. The dimension with the lowest proportion of restrictions was self-care (13.3%) (Table 2). Clinically meaningful restrictions in the dimensions mobility, self-care, usual activities, and pain/discomfort as well as in EQ-VAS and EQ-5D index were observed significantly more often in older patients and in those with a high co-morbidity burden, low Hb-levels, or RBCT need (p < 0.001). Increased problems with anxiety/depression were significantly more frequent in women (p < 0.001) and in patients with lower Hb-levels (p < 0.01). The impact of both of IPSS and IPSS-R on EQ-5D scoring was only marginal. In general, restrictions in all parameters of EQ-5D were significantly more often reported in female patients (p < 0.05, Table 2).

Association of restrictions in HRQoL and demographic and disease factors

To assess possible associations between clinical parameters and HRQoL, univariate and multivariate linear analyses were performed. It was estimated that patients in the reference group of each of demographic and clinical parameters would have a mean score of 0.85 on the EQ-5D index, and 80.85 on the EQ-VAS (Table 3). Relative to these scores, there was a significant loss in HRQL for groups who were older (e.g., 75+ vs. <60 years; index: −0.08; VAS: −7.33), female, or had increased comorbidities, low Hb-levels, or transfusion dependence (Table 3). These differences exceeded the MID on each of the two HRQoL measures (>0.03 on the EQ-5D index and >3.0 on the EQ-VAS). In summary, HRQoL as defined by EQ-5D index and EQ-VAS was more often significantly impaired in older and in female patients and in persons with advanced comorbidities, low Hb levels, and increased transfusion need both in uni- and in multivariate analyses.

Comparison of HRQoL in MDS and in age- and sex-matched reference populations

We compared subgroups of MDS patients with age- and sex-matched reference norms. Overall, patients with MDS were characterized by a small, but significantly lower EQ-5D index (0.74 vs. 0.76) and lower EQ-VAS (69.6 vs. 71.8) than European norms (p < 0.05) (Table 4). However, these differences were too small to fulfil the criteria of MID. In
### Table 1  Demographic and clinical characteristics of MDS-patients—entire cohort and EQ-5D respondents

| Characteristic | Total No. of Patients | Total % | EQ-5D Completed\(^a\) No. of patients | EQ-5D Completed\(^a\) % | EQ-5D not completed No. of patients | EQ-5D not completed % |
|----------------|-----------------------|---------|------------------------------------------|-------------------------|-------------------------------------|-----------------------|
| Entire cohort  | 1 985                 | 100.0   | 1 690                                    | 85.1                    | 295                                 | 14.9                  |
| Age, years     |                       |         |                                          |                         |                                     |                       |
| <60            | 214                   | 10.8    | 187                                      | 11.1                    | 27                                  | 9.2                   |
| 60–75          | 818                   | 41.2    | 707                                      | 41.8                    | 111                                 | 37.6                  |
| 75+            | 953                   | 48.0    | 796                                      | 47.1                    | 157                                 | 53.2                  |
| Gender         |                       |         |                                          |                         |                                     |                       |
| Male           | 1 202                 | 60.6    | 1 039                                    | 61.5                    | 163                                 | 55.3                  |
| Female         | 783                   | 39.4    | 651                                      | 38.5                    | 132                                 | 44.7                  |
| Diagnosis (WHO 2001) |              |         |                                          |                         |                                     |                       |
| RA             | 355                   | 17.9    | 283                                      | 16.7                    | 72                                  | 24.4                  |
| RARS           | 310                   | 15.6    | 276                                      | 16.3                    | 34                                  | 11.5                  |
| RCMD           | 755                   | 38.0    | 651                                      | 38.5                    | 104                                 | 35.3                  |
| RCMD-RS        | 118                   | 5.9     | 102                                      | 6.0                     | 16                                  | 5.4                   |
| RAEB-1         | 239                   | 12.0    | 207                                      | 12.2                    | 32                                  | 10.8                  |
| RAEB-2         | 9                     | 0.5     | 8                                        | 0.5                     | 1                                   | 0.3                   |
| MDS-U          | 81                    | 4.1     | 68                                       | 4.0                     | 13                                  | 4.4                   |
| 5q-Syndrome    | 118                   | 5.9     | 95                                       | 5.6                     | 23                                  | 7.8                   |
| IPSS           |                       |         |                                          |                         |                                     |                       |
| Low risk       | 961                   | 48.4    | 813                                      | 48.1                    | 148                                 | 50.3                  |
| Intermediate-1 | 912                   | 45.9    | 782                                      | 46.3                    | 130                                 | 43.9                  |
| Low/int-1 no cytogenetics\(^b\) | 112 | 5.6 | 95 | 5.6 | 17 | 5.7 |
| IPSS-R         |                       |         |                                          |                         |                                     |                       |
| Very low risk  | 493                   | 24.8    | 433                                      | 25.6                    | 60                                  | 20.3                  |
| Low risk       | 746                   | 37.6    | 646                                      | 38.2                    | 100                                 | 33.9                  |
| Intermediate risk | 420 | 21.2 | 341 | 20.2 | 79 | 26.8 |
| High/very high risk | 121 | 6.1 | 110 | 6.5 | 11 | 3.7 |
| Unknown        | 205                   | 10.3    | 160                                      | 9.5                     | 45                                  | 15.3                  |
| MDS-CI         |                       |         |                                          |                         |                                     |                       |
| Low risk       | 1 276                 | 64.3    | 1 076                                    | 63.7                    | 200                                 | 67.8                  |
| Intermediate risk | 606 | 30.5 | 525 | 31.1 | 81 | 27.5 |
| High risk      | 103                   | 5.2     | 89                                       | 5.3                     | 14                                  | 4.7                   |
| Haemoglobin (g/dL) |                  |         |                                          |                         |                                     |                       |
| ≥10            | 1 076                 | 54.2    | 913                                      | 54.0                    | 163                                 | 55.3                  |
| <10            | 884                   | 44.5    | 768                                      | 45.4                    | 116                                 | 39.3                  |
| Unknown        | 25                    | 1.3     | 9                                        | 0.5                     | 16                                  | 5.4                   |
| Red blood cell transfusion\(^c\) |           |         |                                          |                         |                                     |                       |
| No             | 1 390                 | 70.0    | 1 163                                    | 68.8                    | 227                                 | 76.9                  |
| Yes            | 595                   | 30.0    | 527                                      | 31.2                    | 68                                  | 23.1                  |

\(^a\) Includes EQ-5D completed only, EQ-VAS completed only, and both completed

\(^b\) Patients with cytogenetics failed or not available were included if the diagnosis of MDS was morphologically proven, with <5% bone marrow blasts and at most a single cytopenia according to the IPSS. Based on these criteria, exclusively IPPS low or int-1 patients were included in this cohort

\(^c\) As assessed in the year prior to initial diagnosis

*WHO* World Health Organization, *IPSS* International Prognostic Scoring System, *IPSS-R* Revised International Prognostic Scoring System, *MDS-CI* Myelodysplastic Syndrome-Comorbidity Index, *HCT-CI* Hematopoietic Cell Transplant-Comorbidity Index
|                     | Mobility problem | Self-care problem | Usual activities problem | Pain/discomfort problem | Anxiety/depression problem | EQ-5D: index | EQ-5D: VAS |
|---------------------|------------------|-------------------|--------------------------|-------------------------|---------------------------|--------------|------------|
|                     | % | p  | % | p  | % | p  | % | p  | % | p  | Mean | SD | N  | p  | Mean | SD | N  | p  |
| Total               | 41.0 | 13.3 | 36.1 | 49.5 | 37.9 | 0.74 | 0.23 | 1683 | 69.6 | 20.1 | 1657 |
| Sex                 |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| Male                | 39.1 | 11.6 | 33.6 | 45.5 | 30.1 | 0.77 | 0.22 | 1035 | 70.70 | 20.02 | 1022 |
| Female              | 44.0 | 16.0 | 40.0 | 55.9 | 50.3 | 0.69 | 0.23 | 648 | 67.83 | 20.19 | 635 |
| Age group (years)   |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| <60                 | 18.5 | 2.7 | 26.6 | 31.5 | 40.8 | 0.80 | 0.22 | 184 | 76.65 | 19.35 | 185 |
| 60–75               | 33.0 | 8.5 | 29.1 | 43.5 | 35.9 | 0.78 | 0.21 | 705 | 72.72 | 19.95 | 694 |
| 75+                 | 53.3 | 20.0 | 44.5 | 58.9 | 39.0 | 0.69 | 0.23 | 794 | 65.14 | 19.48 | 778 |
| IPSS                 |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| Low risk            | 42.4 | 13.2 | 49.6 | 53.1 | 39.2 | 0.74 | 0.23 | 809 | 70.20 | 19.84 | 798 |
| Intermediate risk   | 38.2 | 13.1 | 47.7 | 49.3 | 36.8 | 0.75 | 0.22 | 780 | 68.98 | 20.27 | 764 |
| Low/int-1 no cytogenetics | 51.6 | 16.1 | 64.5 | 44.7 | 36.6 | 0.70 | 0.23 | 93 | 69.34 | 21.40 | 94 |
| IPSS-R              |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| Very low risk       | 40.6 | 11.9 | 32.4 | 53.1 | 33.8 | 0.75 | 0.23 | 429 | 71.40 | 19.46 | 422 |
| Low risk            | 40.8 | 13.0 | 36.6 | 49.3 | 38.9 | 0.73 | 0.23 | 645 | 69.05 | 20.38 | 637 |
| Intermediate risk   | 42.4 | 14.4 | 36.5 | 44.7 | 42.9 | 0.73 | 0.22 | 340 | 68.29 | 20.76 | 333 |
| High/very high risk | 40.4 | 14.7 | 35.8 | 52.3 | 36.7 | 0.76 | 0.21 | 109 | 68.61 | 21.16 | 109 |
| Unknown             | 40.6 | 15.0 | 43.1 | 48.8 | 35.0 | 0.74 | 0.22 | 160 | 70.49 | 18.57 | 156 |
| MDS-CI              |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| Low risk            | 33.9 | 10.1 | 31.6 | 44.5 | 37.3 | 0.76 | 0.22 | 1072 | 72.59 | 19.38 | 1053 |
| Intermediate risk   | 51.8 | 18.4 | 42.8 | 57.2 | 38.4 | 0.70 | 0.23 | 523 | 64.92 | 20.09 | 518 |
| High risk           | 63.6 | 22.7 | 50.0 | 64.8 | 42.0 | 0.67 | 0.25 | 88 | 61.26 | 21.76 | 86 |
| Haemoglobin (g/dL)  |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| ≥10                 | 34.5 | 9.2 | 28.9 | 46.9 | 34.3 | 0.77 | 0.22 | 909 | 72.71 | 19.44 | 893 |
| <10                 | 49.2 | 18.3 | 45.0 | 53.2 | 42.4 | 0.70 | 0.23 | 765 | 65.79 | 20.31 | 755 |
| Unknown             | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.95 | 0.10 | 9 | 80.56 | 15.30 | 9 |
| Red blood cell transfusion |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| No                  | 35.9 | 9.8 | 30.9 | 47.5 | 36.2 | 0.76 | 0.22 | 1160 | 71.74 | 19.56 | 1137 |
| Yes                 | 52.2 | 21.0 | 47.4 | 53.9 | 41.7 | 0.69 | 0.24 | 523 | 64.94 | 20.57 | 520 |

**Table 2 Prevalence of problems in distinct dimensions of EQ-5D, EQ-5D index, and EQ-VAS in MDS patients**

IPSS-R Revised International Prognostic Scoring System, MDS-CI myelodysplastic syndrome-comorbidity index. Bold numbers emphasize significant differences (p<0.05).

1 Problem: moderate or severe problems

2 Patients with cytogenetics failed or not available were included if the diagnosis of MDS was morphologically proven, with ≤5% bone marrow blasts and at most a single cytopenia according to the IPSS. Based on these criteria, exclusively IPSS low or int-1 patients were included in EUMDS

3 As assessed in the year prior to initial diagnosis
Table 3 Association of HRQL and demographic and disease characteristics in MDS patients based on univariate and multivariate multilevel linear regression analyses

| Variable                | EQ-5D index (n = 1683 patients) | EQ-VAS (n = 1657 patients) |
|-------------------------|----------------------------------|-----------------------------|
|                         | Univariate                       | Multivariatea               | Univariate                       | Multivariatea               |
|                         | Coef. | 95% CI | p   | Coef. | 95% CI | p   | Coef. | 95% CI | p   |
| Constant                | 0.74 | 0.73   | 0.76| 0.85 | 0.81   | 0.89| 70.71 | 67.98 | 73.44| 0.85 | 0.81   | 0.89| 80.85 | 76.88 | 84.82| <0.001 |
| Age group               |       |        |     |       |        |     |       |        |     |       |        |     |       |        |     |       |
| <60                     |       |        |     |       |        |     |       |        |     |       |        |     |       |        |     |       |
| 60–75                   | −0.03 | −0.06 | 0.01| 0.144| −0.02 | −0.05| 0.02 | 0.287| −3.12 | −6.23 | −0.01 | 0.050| −1.85 | −4.88 | 1.18 | 0.231 |
| 75+                     | −0.11 | −0.14 | −0.07| <0.001| −0.08 | −0.12| −0.05| <0.001| −10.06 | −13.19 | −6.93| <0.001| −7.33 | −10.42| −4.24| <0.001 |
| Sex                     |       |        |     |       |        |     |       |        |     |       |        |     |       |        |     |       |
| Male                    | −0.07 | −0.09 | −0.05| <0.001| −0.08 | −0.10| −0.06| <0.001| −3.24 | −5.17 | −1.32| <0.001| −3.65 | −5.51 | −1.78| <0.001 |
| Female                  | −0.07 | −0.09 | −0.05| <0.001| −0.08 | −0.10| −0.06| <0.001| −3.24 | −5.17 | −1.32| <0.001| −3.65 | −5.51 | −1.78| <0.001 |
| IPSS-R                  |       |        |     |       |        |     |       |        |     |       |        |     |       |        |     |       |
| Very low risk           |       |        |     |       |        |     |       |        |     |       |        |     |       |        |     |       |
| Low risk                | −0.01 | −0.04 | 0.02| 0.414| 0.03 | 0.00 | 0.06| <0.001| −2.19 | −4.59 | 0.21 | 0.073| 1.41 | −1.04 | 3.87 | 0.260 |
| Intermediate/high risk  | −0.01 | −0.04 | 0.03| 0.750| 0.04 | 0.01 | 0.07| <0.001| −2.68 | −5.42 | 0.06 | 0.055| 1.62 | −1.28 | 4.52 | 0.274 |
| Unknown                 | 0.00  | −0.04 | 0.04| 0.909| 0.02 | −0.02| 0.07| 0.254| −0.01 | −3.69 | 3.67 | 0.997| 3.12 | −0.55 | 6.79 | 0.095 |
| MDS-CI                  |       |        |     |       |        |     |       |        |     |       |        |     |       |        |     |       |
| Low risk                |       |        |     |       |        |     |       |        |     |       |        |     |       |        |     |       |
| Intermediate/high risk  | −0.07 | −0.09 | −0.04| <0.001| −0.06 | −0.08| −0.04| <0.001| −7.33 | −9.26 | −5.39| <0.001| −6.22 | −8.15 | −4.28| <0.001 |
| Haemoglobin (g/dL)      |       |        |     |       |        |     |       |        |     |       |        |     |       |        |     |       |
| ≥10                     | −0.07 | −0.09 | −0.04| <0.001| −0.05 | −0.08| −0.03| <0.001| −7.12 | −8.99 | −5.24| <0.001| −5.56 | −7.77 | −3.35| <0.001 |
| <10                     | −0.07 | −0.09 | −0.04| <0.001| −0.05 | −0.08| −0.03| <0.001| −7.12 | −8.99 | −5.24| <0.001| −5.56 | −7.77 | −3.35| <0.001 |
| Red blood cell transfusionb |       |        |     |       |        |     |       |        |     |       |        |     |       |        |     |       |
| No                      | −0.07 | −0.10 | −0.05| <0.001| −0.04 | −0.07| −0.02| <0.001| −7.14 | −9.14 | −5.13| <0.001| −4.03 | −6.18 | −1.87| <0.001 |

IPSS-R Revised International Prognostic Scoring System, MDS-CI Myelodysplastic Syndrome-Comorbidity Index syndrome-comorbidity index. Bold numbers emphasize significant differences (p<0.05).

a Adjusted for all other variables

b As assessed in the year prior to initial diagnosis
Table 4  Comparison of HRQL in MDS patients and age- and sex-matched European reference cohorts

|                     | Mobility problem<sup>a</sup> | Self-care problem<sup>a</sup> | Usual activities problem<sup>a</sup> | Pain/discomfort problem<sup>a</sup> | Anxiety/depression problem<sup>a</sup> | EQ-5D: index | EQ-5D: VAS |
|---------------------|------------------------------|------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|--------------|-------------|
|                     | %                            | %                            | %                                  | %                                  | %                                  | Mean         | SD          | N    | p    | Mean | SD   | N   | p    |
| Entire cohort       | <0.001                       | 0.438                        | <0.001                              | 0.919                               | <0.001                              | 0.019        | 0.029       |
| European Norm       | 33.5                         | 12.4                         | 26.0                                | 48.8                                | 14.9                                | 0.76         | 0.18        | 1683 | 71.8 | 3.1  | 1657 |
| EUMDS               | 41.0                         | 13.3                         | 36.1                                | 49.5                                | 37.9                                | 0.74         | 0.23        | 1683 | 69.6 | 20.1 | 1657 |
| Male                | <0.001                       | 0.409                        | <0.001                              | 0.371                               | <0.001                              | 0.059        | 0.268       |
| European Norm       | 29.4                         | 10.7                         | 23.4                                | 43.9                                | 13.7                                | 0.79         | 0.16        | 1035 | 72.6 | 2.8  | 1022 |
| EUMDS               | 39.1                         | 11.6                         | 33.6                                | 45.5                                | 30.1                                | 0.77         | 0.22        | 1035 | 70.7 | 20.0 | 1022 |
| Female              | 0.142                        | 0.820                        | <0.001                              | 0.355                               | <0.001                              | 0.164        | 0.039       |
| European Norm       | 40.0                         | 15.0                         | 30.1                                | 56.8                                | 16.7                                | 0.72         | 0.19        | 648  | 70.5 | 3.1  | 635  |
| EUMDS               | 44.0                         | 16.0                         | 40.0                                | 55.9                                | 50.3                                | 0.69         | 0.23        | 648  | 67.8 | 20.2 | 635  |
| Age group, <60      | 0.202                        | 0.288                        | <0.001                              | 0.645                               | <0.001                              | 0.019        | 0.508       |
| European Norm       | 13.6                         | 4.9                          | 11.4                                | 28.3                                | 9.8                                 | 0.86         | 0.15        | 184  | 77.3 | 2.9  | 185  |
| EUMDS               | 18.5                         | 2.7                          | 26.6                                | 31.5                                | 40.8                                | 0.80         | 0.22        | 184  | 76.7 | 19.3 | 185  |
| Age group, 60–75    | 0.002                        | 0.179                        | <0.001                              | 0.606                               | <0.001                              | 0.261        | 0.086       |
| European Norm       | 25.4                         | 6.7                          | 20.0                                | 44.5                                | 14.9                                | 0.79         | 0.17        | 705  | 73.1 | 1.7  | 694  |
| EUMDS               | 33.0                         | 8.5                          | 29.1                                | 43.5                                | 35.9                                | 0.78         | 0.21        | 705  | 72.7 | 20.0 | 694  |
| Age group, 75+      | <0.001                       | 0.711                        | <0.001                              | 0.671                               | <0.001                              | 0.207        | <0.001      |
| European Norm       | 45.2                         | 19.1                         | 34.6                                | 57.4                                | 16.0                                | 0.71         | 0.17        | 794  | 69.3 | 1.1  | 778  |
| EUMDS               | 53.3                         | 20.0                         | 44.5                                | 58.9                                | 39.0                                | 0.69         | 0.23        | 794  | 65.1 | 19.5 | 778  |

<sup>a</sup> Problem: moderate or severe problems. Bold numbers emphasize significant differences (p<0.05).
contrast, distinct differences which fulfilled the criteria of a MID were seen in individual components of EQ-5D: a significantly higher proportion of MDS patients reported moderate/severe problems in the dimensions mobility, usual activities, and anxiety/depression compared to the reference populations ($p < 0.001$) (Table 4). Analyses stratified by sex and age depicted most pronounced differences in the dimensions anxiety/depression, and usual activities, in all age groups, and in both sexes ($p < 0.001$). Compared to peers, prevalence of problems in anxiety/depression was most prominent in female (16.7% vs. 50.3%; Fig. 1b) and in younger patients (9.8% vs. 40.8%, $p < 0.001$; Fig. 2a). Restrictions in mobility were most pronounced in male (Fig. 1a) and in older patients (60+ years; $p < 0.01$; Fig. 2c). The dimensions self-care and pain/discomfort were not different between the cohorts (Table 2; Figs. 1 and 2). Differences in EQ-5D index were most pronounced in younger MDS patients (<60 years). EQ-VAS was more often diminished at advanced age (75+ years) as compared to peers ($p < 0.001$; Table 2). These differences fulfilled the criteria of a MID.

**Discussion**

This prospective cohort observational study adds substantial information on the prevalence and clustering of restrictions
in HRQoL in lower-risk patients with MDS at diagnosis. In a cross-sectional analysis, we observed profound restrictions in distinct dimensions of the EQ-5D when compared with European reference populations. Moreover, we identified demographic and clinical factors, which are associated with restrictions in HRQoL.

Fig. 2 Proportion of moderate/severe problems by age group (<60 (a), 60–75 (b), or >75 (c) years old) in patients with MDS (blue bars) as compared to European age- and sex-matched standard population (dark grey). Standard errors indicated as lines. Differences (Δ) of patients with MDS to sex-matched reference group shown when significant (***p < 0.001; **p < 0.01; *p < 0.05; as assessed by Wilcoxon signed rank tests)
Prevalence of restrictions in HRQoL in MDS at initial diagnosis / Factors associated with decreased HRQoL

Data on symptom burden in lower-risk MDS at initial presentation are rare, and limited by small sample size [16, 17], selection bias [7, 16, 17], and analyses performed later after initial diagnosis [7, 11, 16, 18, 19]. In addition, most studies have included patients with higher risk MDS [9–11, 16, 18–20], AML [10, 11] or CMML [11, 16], which precludes precise interpretation. The strength of our study is the large number of observations at initial diagnosis and the parallel analysis of the different parameters of the validated score EQ-5D including EQ-5D VAS, EQ-5D index as well as the different EQ-5D dimensions in a homogenous cohort of lower-risk patients. This is the first report to present details on restrictions in the distinct domains of EQ-5D in MDS, which reveals huge differences in HRQoL-profile in daily activities. These findings are particularly relevant, as studies from the literature reported exclusively EQ-5D summary scores and EQ-5D VAS [16, 20], but lacked a presentation of EQ-5D daily activities.

Our study shows a pronounced symptom burden in many patients with MDS, predominantly in the dimensions pain/discomfort, mobility, anxiety/depression, and usual activities. Moreover, a clustering of symptoms in distinct subgroups of patients is revealed. The low percentage of self-reported problems in the dimension self-care, particularly in elderly is remarkable. This phenomenon has been observed across different cancer types [28] and may be explained by focusing on “washing and dressing” in the definition of self-care, whereas functional capacities like “work, housework, family or leisure activities” are assessed in the dimension “usual activities”.

We demonstrated that advanced age, pronounced co-morbidities, low Hb-levels, RBCT need, and female sex were significantly associated both with a decreased EQ-5D index, and decreased EQ-VAS after adjustment for co-variables. These observations extend data from the literature [7, 8, 18, 20] and define cohorts of patients which are at high risk of decreased HRQoL. Hb levels [7, 18, 20] and transfusion dependence [20] are important predictors of HRQoL, both in this study and in the literature. Effective treatment for anaemia and reduction of transfusion need might thus contribute to improvement and maintenance of HRQoL [17]. Future studies will focus on the prediction of deterioration of HRQoL, and focus on early prevention.

A relevant aspect of our work is the significant difference in symptom burden in patients with MDS as compared to age- and sex matched European reference populations. Thus, dissection of features which are MDS-specific from symptoms which are present in matched general populations is possible. This study reveals an incremental symptom burden in MDS characterized by pronounced age- and sex-dependent differences in the distinct EQ-5D dimensions. Both young and old patients suffer from troublesome MDS-related symptoms. Data from the literature are rare and have been characterized by a small sample size and were restricted to one country [16, 17]. The study of Hellström evaluated HRQoL at later time points after diagnosis, and was focused on selecting anaemic patients with a high probability for response to ESAs for a clinical study [17]. The study of Jansen [16] reported exclusively EQ-5D VAS but lacked a presentation of EQ-5D daily activities for which we show strong differences. Moreover, patients in Jansen’s study were entered at variable time points after diagnosis, and included patients with higher risk MDS and CMML [16].

The high prevalence of anxiety/depression and of limitations in usual activities is more pronounced in women in our study. These observations form the basis to appreciate the relevance of MDS on individual health in a given patient and the opportunity to assist health care providers in managing the relevant symptoms [8]. Thus, patient-centred care will be improved by special attention to patient subgroups [29, 30]. The finding of the difference of depression between our MDS patients and the general population is corroborated by similar evidence in other haematologic conditions. For example, Efficace et al. [31] observed that depression was one of the most impaired psychological domains in a sample of chronic myeloid leukemia patients as compared to their peers in the general population; and, similar to our findings, this impairment was most pronounced in female patients. In agreement with other studies [8, 32, 33], differences by gender were observed with lower HRQoL being more pronounced in females. Although the discussion of causes of disparity in gender-based distribution is beyond the scope of this manuscript, gender-specific evaluations and interventions should be discussed or suggested in patients with MDS.

The relevance of anxiety/depression in patients with MDS is supported by the fact that 9.5% of EU-MDS patients receive antidepressants at baseline [21], and that impairments in depression screening by geriatric depression scale (GDS) are observed in 24% of patients with MDS [34]. Likewise “emotional health” and “uncertainty/sense of control” have been highly ranked by patients and caregivers in a recent study [35]. To address the individual needs of patients with MDS, the novel, disease specific score for MDS, QUALMS [18, 35], is currently applied and validated in the EUMDS-cohort. Our study also confirms that age- and sex-dependent baseline values in HRQoL should be considered when interpreting the results of clinical studies in MDS that use HRQoL as an endpoint, as suggested recently [4, 8].
Strengths of this work are the large number of observations, the well-defined inclusion criteria in a non-interventional registry, the enclosure of newly diagnosed MDS patients within 100 days of the date of the diagnostic bone marrow aspirate, and the parallel analysis of the different parameters of the validated generic score EQ-5D [21]. Based on the use of a generic questionnaire, comparisons with reference populations are possible.

Limitations: Disease-specific scores may more accurately reflect the spectrum in a given disease. To address this aspect, the MDS-specific score QUALMS has been developed recently [18, 35]. QUALMS has been integrated in EUMDS in a recently amended version of the protocol. Based on objectives of this study and the EUMDS registry, analyses have been restricted to IPSS lower-risk MDS. Therefore, this study does not allow conclusions on MDS in general. However, the recently introduced new protocol of the registry will register all subtypes of MDS. Other aspects of HRQoL, which might be relevant for the outcome of patients, e.g., the deterioration of HRQoL over time, have not yet been analyzed. These investigations are currently performed in several studies focusing on the impact of specific interventions on HRQoL.

In summary

This is the first study to analyze prospectively the PRO HRQoL in IPSS lower-risk MDS at diagnosis, and to compare patients with MDS with age- and sex-matched healthy populations. Patients experience profound age- and sex-dependent restrictions in different HRQoL dimensions. Distinct demographic and disease parameters are associated with reduced HRQoL. These observations should form the basis for individualized treatment directed at relief of distinct symptoms. In addition, these results may provide a benchmark in the evaluation of new interventional options aimed at improving HRQoL outcomes.

Supplementary Materials is available at Leukaemia (www.nature.com/leu) providing additional information regarding (i) EQ-5D index and EVS; (ii) on the comparison of patients with MDS and the reference population; (iii) on multivariate analysis; and (iii) on minimally important difference (MID).

Acknowledgements This study was only feasible thanks to the major contributions by all colleagues and patients from participating institutions.

Funding This study was carried out within the EUMDS Registry which is supported by Novartis Oncology. The de Witte is the project leader and C. van Marrewijk is the project manager of the EUMDS Registry. Outside the funding by Novartis Oncology, the following co-authors report grants or personal fees: R. Stauder received research funding and honoraria from Celgene, Teva and Novartis. T. de Witte reports grants from Celgene, personal fees from Incyte, personal fees from Amgen, personal fees from Incyte outside the submitted work. G. Sanz reports personal fees by Celgene. M. Mittelmann reports personal fees by Olifer, Amgen, research grants by Celgene/Neopharm, and advisory roles for Celgene, Amgen, and Janssen. A. Savic personal fees by Seattle Genetics, Novo Nordisk, and Amgen. F. Efficace reports personal fees by Bristol-Myers Squibb, Seattle Genetics, TEVA and Incyte; and research funding by Lundbeck, TEVA, and Amgen. The remaining authors declare that they have no conflict of interest.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Malcovati L, Hellstrom-Lindberg E, Bowen D, Ades L, Cermak J, Del Canizo C, et al. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood. 2013;122:2943–64.
2. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079–88.
3. Greenberg PL, Tuechler H, Schanz I, Sanz G, Garcia-Manero G, Sole F, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120:2454–65.
4. Wildiers H, Heeren P, Puts M, Topinkova E, Janssen-Heijnen ML, Extermann M, et al. International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer. J Clin Oncol. 2014;32:2505–603.
5. Bottomley A, Pe M, Sloan J, Basch E, Bonnetain F, Calvert M, et al. Analysing data from patient-reported outcome and quality of life endpoints for cancer clinical trials: a start in setting international standards. Lancet Oncol. 2016;17:e510–4.
Health-related quality of life in lower-risk MDS patients compared with age- and sex-matched... 1391

6. Patel SS, Gerds AT. Patient-reported outcomes in myelodysplastic syndromes and MDS/MPN overlap syndromes: stepping onto the stage with changing times. Curr Hematol Malig Rep. 2017;12:455–60.

7. Steensma DP, Heptinstall KV, Johnson VM, Novotny PJ, Sloan JA, Camoriano JK, et al. Common troublesome symptoms and their impact on quality of life in patients with myelodysplastic syndromes (MDS): results of a large internet-based survey. Leuk Res. 2008;32:691–8.

8. Efficace F, Gaidano G, Breccia M, Criscuolo M, Cottone F, Caocci G, et al. Prevalence, severity, and correlates of fatigue in newly diagnosed patients with myelodysplastic syndromes. Br J Haematol. 2015;168:361–70.

9. Efficace F, Gaidano G, Breccia M, Voso MT, Cottone F, Angelucci E, et al. Prognostic value of self-reported fatigue on overall survival in patients with myelodysplastic syndromes: a multicentre, prospective, observational, cohort study. Lancet Oncol. 2015;16:1506–14.

10. Deschler B, Ihorst G, Platzbecker U, Gerbing U, Marz E, de Figueiredo M, et al. Parameters detected by geriatric and quality of life assessment in 195 older patients with myelodysplastic syndromes and acute myeloid leukemia are highly predictive for outcome. Haematol. 2013;98:208–16.

11. Buckstein R, Wells RA, Zhu N, Leitch HA, Nevill TJ, Yee KW, et al. Patient-related factors independently impact overall survival in patients with myelodysplastic syndromes: an MDS-CAN prospective study. Br J Haematol. 2016;174:88–99.

12. Efficace F, Cottone F, Abel G, Niscola P, Gaidano G, Bonnetain F, et al. Patient-reported outcomes enhance the survival prediction of traditional disease risk classifications: an international study in patients with myelodysplastic syndromes. Cancer. https://doi.org/10.1002/cncr.3119, 2017.

13. Cannella L, Caocci G, Jacobs M, Vignetti M, Mandelli F, Efficace F. Health-related quality of life and symptom assessment in randomized controlled trials of patients with leukemia and myelodysplastic syndromes: What have we learned? Crit Rev Oncol Hematol. 2015;96:542–54.

14. Cheson BD, Bennett JM, Kantarjian H, Pinto A, Schiffer CA, Nimer SD, et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood. 2000;96:3671–4.

15. Dueck AC, Mendoza TR, Mitchell SA, Reeve BB, Castro KM, Rogak LJ, et al. Validity and reliability of the US National Cancer Institute’s Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). JAMA Oncol. 2015;1:1051–9.

16. Jansen AJ, Essink-Bot ML, Beckers EA, Hop WC, Schippers MR, Van Rhenen DJ. Quality of life measurement in patients with transfusion-dependent myelodysplastic syndromes. Br J Haematol. 2010;151:270–4.

17. Hellstrom-Lindberg E, Gullbransen N, Lindberg G, Ahlgren T, Dahl IMS, Dybedal I, et al. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin plus granulocyte colony-stimulating factor: significant effects on quality of life. Br J Haematol. 2003;120:1037–46.

18. Abel GA, Efficace F, Buckstein RJ, Tinsley S, Jurcic JG, Martins Y, et al. Prospective international validation of the Quality of Life in Myelodysplasia Scale (QUALMS). Haematol. 2016;101:781–8.

19. Fega KR, Abel GA, Motyczkova G, Sherman AE, DeAngelo DJ, Steensma DP, et al. Non-hematologic predictors of mortality improve the prognostic value of the international prognostic scoring system for MDS in older adults. J Geriatr Oncol. 2015;6:288–98.

20. Oliva EN, Finelli C, Santini V, Poloni A, Liso V, Cilloni D, et al. Quality of life and physicians’ perception in myelodysplastic syndromes. Am J Blood Res. 2012;2:136–47.

21. de Swart L, Smith A, Johnston TW, Haase D, Drost J, Fenaux P, et al. Validation of the revised international prognostic scoring system (IPSS-R) in patients with lower-risk myelodysplastic syndromes: a report from the prospective European LeukaemiaNet MDS (EUMDS) registry. Br J Haematol. 2015;170:372–83.

22. Brooks R. EuroQol: the current state of play. Health Policy. 1996;37:53–72.

23. Greiner W, Weijnen T, Nieuwenhuizen M, Oppe S, Badia X, Busschbach J, et al. A single European currency for EQ-5D health states. Results from a six-country study. Eur J Health Econ. 2003;4:222–31.

24. Langelaa M, de Boer MR, van Nispen RM, Wouters B, Moll AC, van Rens GH. Impact of visual impairment on quality of life: a comparison with quality of life in the general population and with other chronic conditions. Ophthalmic Epidemiol. 2007;14:119–26.

25. Szende A, Williams A. Measuring self-reported population health—an International Perspective based on EQ-5D. EuroQol Group, 2012.

26. Lubetkin EI, Jia H, Franks P, Gold MR. Relationship among sociodemographic factors, clinical conditions, and health-related quality of life: examining the EQ-5D in the US general population. Qual Life Res. 2005;14:2187–96.

27. Jaeschke R, Singer J, Guyatt GH. Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials. 1989;10:407–15.

28. Pickard AS, Jiang R, Lin H-W, Rosenbloom S, Cella D. Using patient-reported outcomes to compare relative burden of cancer: EQ-5D and functional assessment of cancer therapy-general in eleven types of cancer. Clin Ther. 2016;38:769–77.

29. Frosch ZA, Abel GA. Assessing quality of care for the myelodysplastic syndromes. Curr Hematol Malig Rep. 2016;11:402–7.

30. Burgstaller S, Wiesinger P, Stauder R. Myelodysplastic syndromes in the elderly: treatment options and personalized management. Drugs Aging. 2015;32:891–905.

31. Efficace F, Breccia M, Cottone F, Okumura I, Doro M, Riccardi F, et al. Psychological well-being and social support in chronic myeloid leukemia patients receiving lifelong targeted therapies. Support Care Cancer. 2016;24:8887–94.

32. Wang XS, Cleeland CS, Mendoza TR, Yun YH, Wang Y, Okayama T, et al. Impact of cultural and linguistic factors on symptom reporting by patients with cancer. J Natl Cancer Inst. 2010;102:732–8.

33. Valletiny C, Kemmler G, Stauder R. Age, sex and gender impact multidimensional geriatric assessment in elderly cancer patients. J Geriatr Oncol. 2012;3:17–23.

34. Hamaker ME, Mitrovic M, Stauder R. The G8 screening tool detects relevant geriatric impairments and predicts survival in elderly patients with a haematological malignancy. Ann Hematol. 2014;93:1031–40.

35. Abel GA, Klaassen L, Lee SJ, Young NL, Cannella L, Steensma DP, et al. Patient-reported outcomes for the myelodysplastic syndromes: a new MDS-specific measure of quality of life. Blood. 2014;123:451–2.
Affiliations

Reinhard Stauder1 · Ge Yu2 · Karin A. Koinig1 · Tim Bagguley2 · Pierre Fenaux3 · Argiris Symeonidis4 · Guillermo Sanz5,6 · Jaroslav Cermak7 · Moshe Mittelman8 · Eva Hellström-Lindberg9 · Saskia Langemeijer10 · Mette Skov Holm11 · Krzysztof Mądry12 · Luca Malcovati13 · Aurelia Tatic14 · Ulrich Germing15 · Aleksandar Savic16 · Corine van Marrewijk10 · Agnès Guerci-Bresler17 · Elisa Luño18 · Jackie Droste10 · Fabio Efficace19 · Alex Smith2 · David Bowen20 · Theo de Witte21

1 Department of Internal Medicine V (Hematology and Oncology), Medical University Innsbruck, Innsbruck, Austria
2 Epidemiology and Cancer Statistics Group, Department of Health Sciences, University of York, New York, United Kingdom
3 Service d’Hématologie, Hôpital Saint-Louis, Assistance Publique des Hôpitaux de Paris (AP-HP) and Université Paris 7, Paris, France
4 Department of Medicine, Division of Hematology, University of Patras Medical School, Patras, Greece
5 Department of Hematology, Hospital Universitario y Politécnico La Fe, Valencia, Spain
6 CIBERONC, Instituto Carlos III, Madrid, Spain
7 Department of Clinical Hematology, Institute of Hematology & Blood Transfusion, Praha, Czech Republic
8 Department of Medicine A, Tel Aviv Sourasky (Ichilov) Medical Center and Sackler Medical Faculty, Tel Aviv University, Tel Aviv, Israel
9 Department of Medicine, Division of Hematology, Karolinska Institutet, Stockholm, Sweden
10 Department of Hematology, Radboud University Medical Center, Nijmegen, Netherlands
11 Department of Hematology, Aarhus University Hospital, Aarhus, Denmark
12 Department of Hematology, Oncology and Internal Medicine, Warszawa Medical University, Warszawa, Poland
13 Department of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy
14 Center of Hematology and Bone Marrow Transplantation, Fundeni Clinical Institute, Bucharest, Romania
15 Department of Hematology, Oncology and Clinical Immunology, Universitätsklinik Düsseldorf, Düsseldorf, Germany
16 Clinic of Hematology - Clinical Center of Vojvodina, University of Novi Sad, Novi Sad, Serbia
17 Service d’Hématologie, Center Hospitalier Universitaire Brabois Vandoeuvre, Nancy, France
18 Servicio d’Hematología, Servicio de Salud del Principado de Asturias Oviedo, Oviedo, Spain
19 Fondazione GIMEA Onlus, Rome, Italy
20 St. James’s Institute of Oncology, Leeds Teaching Hospitals, Leeds, United Kingdom
21 Department of Tumor Immunology - Nijmegen Center for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, Netherlands